Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 92Recurrence 12Neoplasms, Plasma Cell 10Immunoglobulin Light-chain Amyloidosis 6Paraproteinemias 4Neoplasms 4Amyloidosis 3Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Immunoproliferative Disorders 2Hematologic Diseases 2Disease Progression 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Sezary Syndrome 1Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Peripheral Nervous System Diseases 1Pathologic Complete Response 1Neoplasms by Histologic Type 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Immune System Diseases 1

Interventions

Sorafenib 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sarcoma, Myeloid × Bortezomib × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡